Do you consider dual biologic therapy in patients with ABPA that remain steroid dependent despite the use of omalizumab?  

The treatment of ABPA can be so challenging, but this is something that I have not seriously considered at this point. Unfortunately, in general, the evidence for biologics in the treatment of ABPA currently is heterogeneous. Furthermore, many studies are descriptive case reports/series or based on ...

Many cases are not always clear-cut ABPA and overlap in the spectrum of eosinophilic asthma; for such patients might be worth switching biologics from omalizumab to another one (which is also more effective for asthma); at least worth a try.